MDxHealth SA (NASDAQ:MDXH) completes $15 million acquisition of Bio-Techne Corporation’s ExoDx business, enhancing its precision diagnostics portfolio. The company offers a range of tests targeting prostate cancer and UTI detection in a market worth $4.9 billion, showing strong potential for growth and “sticky adoption.”

On August 5, 2025, MDxHealth SA signed a definitive agreement for the acquisition, structured with $5 million in stock paid at closing and $2.5 million annually over four years. The deal aims to strengthen the company’s position in the precision diagnostics market.

Headquartered in Herstal, Belgium, MDxHealth SA is a commercial-stage precision diagnostics company founded in 2003. With tests like Select mdx, Confirm mdx, and Resolve mdx, the company is dedicated to improving patient care and healthcare economics through innovative diagnostics solutions.

While MDxHealth SA presents investment opportunities, some AI stocks may offer greater upside potential. For those seeking undervalued AI stocks with potential benefits from current economic trends, consider exploring opportunities beyond MDXH.

Read more at Yahoo Finance: MDxHealth Completes Bio Techne ExoDx Acquisition to Bolster Precision Diagnostics